Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Antibiotics Clear all
Terminated Phase 4 Interventional Results available

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

NCT05156437
View directory record Official record
Conditions
Endocarditis
Interventions
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

NCT01232595
View directory record Official record
Conditions
Moderate Clostridium Difficile Infection
Interventions
LFF571, Vancomycin (POC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Preventing Complications in Cleft Palate Repair With Antibiotics

NCT00760006
View directory record Official record
Conditions
Cleft Palates
Interventions
Unasyn, saline solution
Drug · Other
Lead sponsor
Joseph Losee
Other
Eligibility
3 Months to 18 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT01271998
View directory record Official record
Conditions
Bacterial Infection
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Infected Blood Dendritic Cells in Heart Disease Risk

NCT01568944
View directory record Official record
Conditions
Chronic Periodontitis
Interventions
Oral Antibiotic and Oral Rinse, Standard Treatment
Drug · Procedure
Lead sponsor
Augusta University
Other
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 22, 2026, 2:52 AM EDT
Terminated Phase 2 Interventional Results available

Tofacitinib For Treatment Of Chronic Pouchitis

NCT04580277
View directory record Official record
Conditions
Pouchitis, Ileal Pouchitis, Ileal Pouch
Interventions
Tofacitinib 10 mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563433
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Pilot Study

NCT04608019
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Antibiotics, Tailored Treatment
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
6 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis

NCT00462020
View directory record Official record
Conditions
Perforated Appendicitis
Interventions
5 days of IV antibiotics (ceftriaxone and metronidazole), Home with oral antibiotics when eating (ampicillin/clavulanic acid)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Not applicable Interventional

Randomized Trial to Assess PO Versus IV Antibiotics

NCT01714596
View directory record Official record
Conditions
Wound Infection
Interventions
PO versus IV antibiotics Route of administration evaluation
Other
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 84 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 22, 2026, 2:52 AM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 22, 2026, 2:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Antibiotic Bowel Preparation in Gynecologic Oncology Surgery

NCT05210556
View directory record Official record
Conditions
Surgical Site Infection, Surgical Complication, Gynecologic Cancer
Interventions
Diagnosed with Surgical Site Infection
Other
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
778 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

NCT00989872
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
EDP-322
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Oct 22, 2026, 2:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feasibility Assessment of Risk Stratification and Oral Challenge in Hospitalized Children at Low Risk for Antibiotic Allergy

NCT04441021
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Penicillin Allergy Risk Stratification and Evaluation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

NCT02257918
View directory record Official record
Conditions
Gonorrhoea
Interventions
AZD0914, Ceftriaxone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

"Clinical Trials to Enhance Elders' Oral Health" ("TEETH")

NCT00004640
View directory record Official record
Conditions
Tooth Loss, Periodontal Disease, Tooth Decay
Interventions
Chlorhexidine rinse
Drug
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 75 Years
Enrollment
1,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 22, 2026, 2:52 AM EDT
Terminated Phase 4 Interventional

Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis

NCT00245440
View directory record Official record
Conditions
Maxillary Sinusitis
Interventions
Azithromycin, Telithromycin
Drug
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Taylors, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical and Surgical Treatment of Teeth With Periodontal Disease

NCT05252000
View directory record Official record
Conditions
Periodontal Diseases
Interventions
mechanical debridement, adjunctive aPDT, sham aPDT
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

Control of Periodontal Infections

NCT01098448
View directory record Official record
Conditions
Periodontitis
Interventions
scaling and root planing, local tetracycline, systemic metronidazole and amoxicillin, surgery, local antibiotics and systemic metronidazole and amoxicillin, local tetracycline and periodontal surgery, periodontal surgery and systemic metronidazole and amoxicillin, surgery, local tetracycline, systemic metronidazole and amoxicillin
Other · Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
20 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 22, 2026, 2:52 AM EDT
Recruiting Phase 4 Interventional

Extended Oral Antibiotic Prophylaxis in Diabetic Fracture Patients

NCT07561541
View directory record Official record
Conditions
Fracture Lower Leg, Diabetes, Fracture Fixation, Internal
Interventions
Cefadroxil 500 mg Capsules, Clindamycin, Bactrim DS
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Los Angeles, California • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 2:52 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

NCT05327803
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions
Epetraborole, Placebo
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 2:52 AM EDT
Recruiting Phase 4 Interventional

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

NCT03014687
View directory record Official record
Conditions
Antibiotics, Pituitary Adenoma
Interventions
Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 84 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 22, 2026, 2:52 AM EDT
Completed Phase 4 Interventional Results available

Impact of Oral Antibiotic Treatment on C. Difficile

NCT02057198
View directory record Official record
Conditions
C. Difficile, Diarrhea, Enterocolitis
Interventions
Fidaxomicin, Metronidazole, Vancomycin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 22, 2026, 2:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse.

NCT07191262
View directory record Official record
Conditions
Extraction Sites After Removal and Bone Replacement Grafting at Extraction Sockets of Dentally Hopeless Single-rooted Teeth
Interventions
0.12% CHX and Essential Oil mouthrinse, 2.6% EDTA and 0.2% EDTA mouth rinse
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 2:52 AM EDT